Search results for: Amgen
Filter search results
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…Bruce (Amgen) on a General Outcome-based Value Attribution Framework for Combination Therapies, presented in a recently published paper. The Roundtable The roundtable, hosted by OHE and sponsored by Amgen, was…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…Towse and Lotte Steuten) and Amgen (Mickael Lothgren and Andrew Bruce) contributes to the emerging debate as to why a new approach is required to address the value attribution problem…
The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
1 April 2014
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…OHE/Amgen paper on this was described in an OHE blog, and a paper is expected soon from a Takeda sponsored group looking at solutions in England. Competition law differs by…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
…in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis[1]. A…
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
…by a consortium of five pharmaceutical companies: Amgen, GSK, Lilly, Novartis, and Sanofi. References: Towse, A., Garau, M., Mohr, P. and Messner, D.A., 2015. Futurescapes: expectations in Europe for relative…
Recently Published: Payer Perspectives on Future Acceptability of Comparative Effectiveness and Relative Effectiveness Research
18 August 2015
…companies: Amgen, GSK, Lilly, Novartis and Sanofi. The study included interviews with and a survey of ‘key informants’ (senior officials representing public and private payers, HTA bodies and Government…
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
1 February 2021
This research paper examines whether value of a life estimates used in economic evaluation differs between government departments in a selection of developed countries. The authors find that generally estimates…